

**THE JAMES CROOKS MEMORIAL FELLOWSHIP IN CLINICAL PHARMACOLOGY &
THERAPEUTICS**

**Scottish Charity Number: SC052561
Accounts for the year to 31 December 2025**

Contents

Report of the Trustees
Report by Independent Examiner
Accounts
Notes to the Accounts
Appendices of Investments

The James Crooks Memorial Fellowship in Clinical Pharmacology & Therapeutics

Report of the Trustees for the year to 31 December 2025

<i>Trustees:</i>	<i>1st Named Trustee for:</i>	<i>Date/Manner of Appointment</i>
Professor Chim Lang, University of Dundee, Division of Molecular and Clinical Medicine, Mailbox 2, Ninewells Hospital, Dundee DD1 9SY.	Fee Notes / Contract Notes / Tax	Position held at Dundee University within Department in Clinical Pharmacology
Professor Isla Mackenzie, Cardiovascular Medicine, University of Dundee Medical School, Mailbox 2, Ninewells Hospital, Dundee Dd1 9SY.		Assumed 24.11.2022

Appointment of trustees

Trustees are nominated by the then existing trustees and their appointment confirmed by formal Deed of Assumption.

Trustee Induction and training

The trustees deal appropriately as regards induction and training on any new trustees appointed. This includes awareness of a trustee's responsibilities, the governing document, administrative procedures, and the history and philosophical approach of the charity. A new trustee will receive copies of the previous year's accounts, minutes of recent trustee meetings and a copy of the OSCR booklet "Guidance and good practice for Charity Trustees", if appropriate.

Agents and Administrators for the Trust (and principal address of the Charity)

Thorntons Law LLP, Whitehall House, 33 Yeaman Shore, Dundee DD1 4BJ

Investment Managers

Evelyn Partners, 177 Bothwell Street, Glasgow G2 7ER.

Independent Examiner

David Taylor CA, Partner, Henderson Loggie LLP, The Vision Building, 20 Greenmarket, Dundee DD1 4QB

Charity Reference

Scottish Charity No: SC052561

Constitution and Objects

Deed of Trust by Professor Peter Denham Griffiths, 52 Albany Road, West Ferry, Dundee, (Dean of the Faculty of Medicine and Dentistry), Professor Denis Gordon McDevitt, (Professor of Clinical Pharmacology) 1 Godfrey Street, Barnhill, Dundee and Professor Ian Hosie Stevenson, (Professor of Pharmacology) 7 Scotswood Terrace, Dundee in their capacities in the University of Dundee, and registered with OSCR on 23 May 2023.

Beneficiaries include all or any one or more of:- (a) The University Department of Pharmacology and Clinical Pharmacology; (b) The Pharmaceutical Industry; (c) Academic Departments of Pharmacology, Clinical Pharmacology and Therapeutics, in particular, but not exclusively, in relation to the award biennially by the University of Dundee upon the recommendation of the Fellowship Trustees of a fellowship in one or more of the following ways:

By inviting an acknowledged expert in the field of Pharmacology, Clinical Pharmacology or Therapeutics to spend a short period of at least one week in the University Department of Pharmacology and Clinical Pharmacology, during which period the fellow appointed will give a James Crooks memorial Lecture and a series of seminars for staff and postgraduate students;

Report of the Trustees for the year to 31 December 2025 (cont)

By supporting a young research worker in Clinical Pharmacology or related fields from outwith the University for an extended period of research of up to two months within the University Department of Pharmacology and Clinical Pharmacology; and

By supporting a member of the University's staff working in Clinical Pharmacology or related fields in undertaking a period of further training in a Department of Clinical Pharmacology either within a University or within the pharmaceutical industry;

Organisation

The day-to-day administration is carried out by Thorntons Law LLP, as agents for the Trust. The trustees meet annually to consider grant applications and to review any other relevant aspects of the Trust's affairs.

Achievements and performance

The trustees have continued their policy of making donations to those charities and institutions as directed in the trust deed.

Risk Management

The trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the trust, and are satisfied that systems are in place to mitigate exposure to those risks. The trustees consider variability of investment returns to constitute the charity's major financial risk. This is mitigated by retaining expert investment managers and having a diversified investment portfolio.

Investment Policy and Performance

There are no restrictions in the Deed on the trustees' power to invest. The policy is, long term, to adopt a medium risk investment strategy, including equity investments, to produce a balance of income and capital growth.

Financial Position

The financial position is as set out on pages 5 and 6.

Reserves Policy

The reserves of the Trust originate from original and subsequent capital bequests, together with the movement in the value of investments, and accumulated revenue. The trustees have adopted a reserves policy that ensures the continuing ability of the Trust to meet its objectives. The level of free reserves held at 31 December 2025 was **£208,977.23** (2024 £198,666.61).

Future Strategy

No changes are presently envisaged in the trust's policies as outlined above.

Independent Examiner's Report to the trustees of The James Crooks Memorial Fellowship in Clinical Pharmacology & Therapeutics

I report on the accounts of the charity for the period ended 31 December 2024 which are set out on pages 5 to 9.

This report is made to the trustees, as a body, in accordance with the terms of my engagement. My work has been undertaken to enable me to report my opinion set out below and for no other purpose. To the fullest extent permitted by law I do not accept or assume responsibility to anyone other than the trustees, as a body, for my work or for this report.

Respective responsibilities of trustees and examiner

The trustees are responsible for the preparation of the accounts in accordance with the terms of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). The trustees consider that the audit requirement of Regulation 10(1) (a) to (c) of the 2006 Accounts Regulations does not apply. It is my responsibility to examine the accounts as required under section 44(1) (c) of the Act and to state whether particular matters have come to my attention.

Basis of independent examiner's statement

My examination is carried out in accordance with regulation 11 of the 2006 Accounts Regulations. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeks explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently I do not express an audit opinion on the view given by the accounts.

Independent examiner's statement

In the course of my examination, no matter has come to my attention:

1. which gives me reasonable cause to believe that in any material respect the requirements:
 - to keep accounting records in accordance with section 44(1) (a) of the 2005 Act and Regulation 4 of the 2006 Accounts Regulations, and
 - to prepare accounts which accord with the accounting records and comply with Regulation 8 of the 2006 Accounts Regulations
 have not been met, or;
2. to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.

David Taylor

David Taylor CA
 Partner
 For and on behalf of Henderson Loggie LLP
 The Vision Building
 20 Greenmarket
 Dundee
 DD1 4QB

The James Crooks Memorial Fellowship in Clinical Pharmacology & Therapeutics

Receipts and Payments Account for the year ended 31 December 2025

	<i>Schedule/ Appendix</i>	2025 £	2024 £
Receipts			
Investment income	<i>Sch 1</i>	3,780.23	3,866.51
Sale proceeds from investments	<i>App 2</i>	<u>43,478.15</u>	<u>115,624.34</u>
Total receipts		<u>47,258.38</u>	<u>119,490.85</u>
Payments			
Charitable activities	<i>Sch 2</i>	4,059.99	4,700.00
Governance	<i>Sch 3</i>	2,754.00	4,141.68
Cost of generating funds	<i>Sch 4</i>	2,206.21	907.87
Purchase of Investments	<i>App 2</i>	<u>39,804.36</u>	<u>113,008.06</u>
Total payments		<u>48,824.56</u>	<u>122,757.61</u>
(Deficit) for the year		<u>(1,566.18)</u>	<u>(3,266.76)</u>

All funds are unrestricted.

The James Crooks Memorial Fellowship in Clinical Pharmacology & Therapeutics

Statement of Balances as at 31 December 2025

	<i>Schedule/ Appendix</i>	2025 £	2024 £
Cash on deposit and on hand			
Opening balance		3,312.32	6,579.08
(Deficit) for the year		(1,566.18)	(3,266.76)
Closing balance		<u>1,746.14</u>	<u>3,312.32</u>
Reserves			
Unrestricted Funds		<u>1,746.14</u>	<u>3,312.32</u>
Investments			
As valued at 31.12.25	<i>App 3</i>	<u>212,052</u>	<u>200,154</u>
Estimated Liabilities as at 31.12.25			
Thorntons Law LLP, administration fees		3,120.00	3,120.00
Evelyn Partners, portfolio management fees		578.91	557.71
Independent Examiner Fee		1,122.00	1,122.00
		<u>4,820.91</u>	<u>4,799.71</u>

Approved by the Trustees and signed on their behalf:

Chim Lang

10 Sept 2026


Date

The James Crooks Memorial Fellowship in Clinical Pharmacology & Therapeutics

Statement of Balances as at 31 December 2025

	<i>Schedule/ Appendix</i>	2025 £	2024 £
Cash on deposit and on hand			
Opening balance		3,312.32	6,579.08
Deficit for the year		(1,566.18)	(3,266.76)
Closing balance		<u>1,746.14</u>	<u>3,312.32</u>
Reserves			
Unrestricted Funds		<u>1,746.14</u>	<u>3,312.32</u>
Investments			
As valued at 31.12.25	<i>App 3</i>	<u>212,052</u>	<u>200,154</u>
Estimated Liabilities as at 31.12.25			
Thorntons Law LLP, administration fees		3,120.00	3,120.00
Evelyn Partners, portfolio management fees		578.91	557.71
Independent Examiner Fee		1,177.20	1,122.00
		<u>4,876.11</u>	<u>4,799.71</u>

Approved by the Trustees and signed on their behalf:

Signed by:

 CAB5E5C3FA3F455...

Date

2/9/2026

The James Crooks Memorial Fellowship in Clinical Pharmacology & Therapeutics

Schedule 1	2025	2024
Income received	£	£
Dividends and interest, per Appendix 1	3,780.23	3,866.51

Schedule 2 **Charitable Activities**

Distributions made in year (£500 each to 4 individuals)	2,500.00	2,000.00
Support costs (Schedule 3)	1,559.99	2,700.00
	4,059.99	4,700.00

Schedule 3 **Support costs**

	Governance	Charitable	2025
	£	Activities	Total
		£	£
Thorntons, their fee for Trust administration, commissions, posts etc. for the period to 31.12.25 (inc VAT)	1,560.00	1,559.99	3,119.99
Henderson Loggie – independent examination of the 2024 Accounts	1,122.00	-	1,122.00
Evelyn Partners – LEI renewal	72.00	-	72.00
	2,754.00	1,559.99	4,313.99

Schedule 3			
Support costs	Governance	Charitable	2024
	£	Activities	Total
		£	£
Thorntons, their fee for Trust administration, commissions, posts etc. for the period to 31.12.24 (inc VAT)	2,700.00	2,700.00	5,400.00
Henderson Loggie – independent examination of the 2023 Accounts	1,020.00	-	1,020.00
Renewal Advisory Remuneration – AJ Bell	300.63	-	300.63
Custody Charges	121.05	-	121.05
	4,141.68	2,700.00	6,841.68

No Trustees received any remuneration or expenses from the Trust during this or the preceding year.

The Trust has no employees.

The James Crooks Memorial Fellowship in Clinical Pharmacology & Therapeutics

Schedule 4

Cost of generating funds

	2025	2024
	£	£
Evelyn Partners, portfolio management fees	<u>2,206.21</u>	<u>907.87</u>

Schedule 5

Statement of Revenue balance as at 31.12.25

	2025	2024
	£	£
Income received in the year	3,780.23	3,883.20
Distributions paid to beneficiaries	(2,500.00)	(2,000.00)
Support costs	(1,559.99)	(2,700.00)
	(279.76)	(816.80)
Balance as at 31.12.24	(1,502.60)	(685.80)
Balance as at 31.12.25	(1,782.36)	(1,502.60)

Notes to the Accounts and General Notes regarding the Financial Services and Markets Act 2000, Law Society Rules and related matters

Basis of Preparation

The Accounts are prepared in accordance with the Charities Accounts (Scotland) Regulations 2006 (as amended).

Investments etc

In these Accounts stocks and shares, gilts, debentures and warrants are valued at their Stock Market value, if listed on a registered Stock Exchange, or otherwise at either (i) the latest available valuation known to us or (ii) cost, at our discretion. Unit Trusts are valued at their approximate bid price. Life Assurance policies are not valued.

Realised gains or losses are transferred to Capital. Unrealised appreciation or depreciation in the value of investments - as compared to their CGT base costs - is dealt with under "Adjustment on revaluation/rebasing".

Contract Notes

In terms of our Law Society Rules we are required to forward copies of all Contract Notes relating to the sale or purchase of investments to clients. In the case of Trusts we fulfil this requirement by forwarding a copy to the first named independent Trustee (i.e. a Trustee who is not a partner/nominee company of our firm) based on the order of Trustees set out on the first page of the Trust Accounts, unless otherwise agreed.

Stockbroker Commissions

As reimbursement of stockbroker commissions received on the purchase or sale of stocks and shares is administratively expensive and as the amounts involved are normally fairly minor, our practice is *not* to reimburse such commissions to the Trust, but to take them into account in the overall assessment of our fees. Any commissions received through Thorntons Investment Managers are retained in full unless otherwise agreed.

Investment Managers

The Trustees approve the continued appointment of the Investment Managers as detailed in the General Information section in these Accounts, and on the same basis as contained in the Investment and Financial Services Terms of Business Agreement currently in force.

Nomineeship:

The trustees approve the appointment of the nominee company as detailed in the General Information section in these Accounts to continue to hold certain or all of the investments owned by the trustees, and that on the same basis as contained in the Investment and Financial Services Terms of Business Agreement currently in force.

Independent Examiner

The trustees approve the continued appointment of the Independent Examiner as detailed in the Report of the trustees in these Accounts.

Going Concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the Trust has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

The James Crooks Memorial Fellowship in Clinical Pharmacology and Therapeutics

Appendix 1

Accounts for the period ended 31 December 2025

£

Dividends & Interest received in the period ended 31 December 2025

06/01/2025 J P MORGAN GLOBAL GROWTH & INCOME P ORD GBP0.05	135.32
20/01/2025 FIDELITY GLOBAL DIVIDEND W INC	21.84
30/01/2025 UK GOVT 0.125% 30/01/26	6.05
31/01/2025 TB EVENLODE INVESTMENT FUNDS ICVC TB EVENLODE INCOME F	80.49
31/01/2025 ARTEMIS INV FUNDS CORPORATE BOND	49.47
31/01/2025 UK GOVT 3.25% 31/01/33	153.76
31/01/2025 GUINNESS ASSET MANAGEMENT GLOBAL EQUITY INCOME Z	78.39
11/02/2025 BNY MELLON GLOBAL FUNDS US EQUITY INCOME	54.49
18/02/2025 FIDELITY GLOBAL DIVIDEND W INC	21.84
07/03/2025 UK GOVT 3.75% 07/03/27	170.18
18/03/2025 FIDELITY GLOBAL DIVIDEND W INC	21.84
31/03/2025 VONTOBEL FUND TWENTYFOUR SHORT TERM BOND	83.75
31/03/2025 BAILLIE GIFFORD UK & BAL FDS ICVC	116.35
09/04/2025 JPMORGAN GROWTH & INCOME ORD 5P	135.32
22/04/2025 FIDELITY INV FDS GLOBAL DIVIDEND FUND	62.42
22/04/2025 UK GOVT 3.5% 22/10/25	157.45
30/04/2025 ARTEMIS INV FUNDS CORPORATE BOND	108.92
30/04/2025 TB EVENLODE INVESTMENT FUNDS ICVC TB EVENLODE INCOME F	115.10
09/05/2025 BNY MELLON GLOBAL FUNDS US EQUITY INCOME	49.35
16/05/2025 FINSBURY GROWTH & INCOME TRUST ORD 25P	89.14
19/05/2025 FIDELITY GLOBAL DIVIDEND INC	23.13
18/06/2025 FIDELITY GLOBAL DIVIDEND INC	23.13
23/06/2025 JPMORGAN GROWTH & INCOME ORD 5P	89.72
30/06/2025 VONTOBEL FUND TWENTYFOUR SHORT TERM BOND	80.01
30/06/2025 BAILLIE GIFFORD UK & BAL FDS ICVC	76.66
18/07/2025 FIDELITY GLOBAL DIVIDEND INC	23.13
30/07/2025 UK GOVT 0.125% 30/01/26	6.05
31/07/2025 TB EVENLODE INVESTMENT FUNDS ICVC TB EVENLODE INCOME F	82.97
31/07/2025 UK GOVT 3.25% 31/01/33	153.76
31/07/2025 ARTEMIS INV FUNDS CORPORATE BOND	111.22
31/07/2025 UK GOVT 0.25% BDS 31/07/31	6.25
01/08/2025 GUINNESS ASSET MANAGEMENT GLOBAL EQUITY INCOME Z	92.48
11/08/2025 BNY MELLON GLOBAL FUNDS US EQUITY INCOME	47.16
18/08/2025 FIDELITY GLOBAL DIVIDEND INC	23.13
08/09/2025 UK GOVT 3.75% 07/03/27	170.18
18/09/2025 FIDELITY GLOBAL DIVIDEND INC	23.13
30/09/2025 VONTOBEL FUND TWENTYFOUR SHORT TERM BOND	74.03
30/09/2025 BAILLIE GIFFORD UK & BAL FDS ICVC	78.47
01/10/2025 JPMORGAN GLOBAL BOND	0.01
07/10/2025 JPMORGAN GROWTH & INCOME ORD 5P	90.51
20/10/2025 FIDELITY GLOBAL DIVIDEND INC	23.13
22/10/2025 UK GOVT 3.5% 22/10/25	157.45
31/10/2025 TB EVENLODE INVESTMENT FUNDS ICVC TB EVENLODE INCOME F	83.00
31/10/2025 ARTEMIS INV FUNDS CORPORATE BOND	110.85
31/10/2025 M&G INVB FUNDS ASIAN STERLING	41.34
10/11/2025 BNY MELLON GLOBAL FUNDS US EQUITY INCOME	45.48
18/11/2025 FIDELITY GLOBAL DIVIDEND INC	23.13
18/12/2025 FIDELITY GLOBAL DIVIDEND INC	23.13
30/12/2025 VONTOBEL FUND TWENTYFOUR SHORT TERM BOND	83.00
31/12/2025 JPMORGAN GROWTH & INCOME ORD 5P	90.51
31/12/2025 BAILLIE GIFFORD UK & BAL FDS ICVC	77.57

3,745.19

Interest received for the period to 31 December 2025

35.04

3,780.23

The James Crooks Memorial Fellowship in Clinical Pharmacology and Therapeutics

Appendix 2

Accounts for the period ended 31 December 2025

Investment sales and purchases for the period ended 31 December 2025

	Units	Investment	£
Sales			
31/01/2025		0 ARTEMIS INV FUNDS CORP BOND - equalisation	6.03
07/04/2025	800	JPMORGAN GLOBAL GROWTH & INCOME ORD 5P	3,867.22
09/05/2025	35	TRIUM UCITS PLATFORM EMISSIONS IMPROVERS ACC	3,531.50
12/06/2025	1,013	FINSBURY GROWTH & INCOME ORD 25P	9,269.05
13/06/2025	850	PREMIER MITON INVESTMENT FUNDS US OPPS ACC	3,444.20
12/08/2025	731.022	FIRST SENTIER INVESTORS ASIA PACIFIC	6,075.30
09/10/2025	66.5583	MONTLAKE UCITS MYGALE EVENT DRIVEN	8,135.75
22/10/2025	8,997	UK GOVT 3.5% BDS 22/10/25	8,997.00
31/10/2025		0 M&G INVB FUNDS ASIAN STERLING - equalisation	152.10
			43,478.15
Purchases			
07/04/2025	5,000	UK GOVT 0.25% BDS 31/07/31	3,945.31
13/06/2025	310	MORGAN STANLEY FUNDS GLOBAL BRANDS	6,024.20
13/06/2025	4,610	ARTEMIS UK SELECT FUND G ACC	6,877.20
12/08/2025	4,532	M&G INVB FUNDS ASIAN STERLING	6,027.56
20/10/2025	55	AQR MANAGED FUTURES	7,933.20
23/10/2025	10,617	UK GOVT 0.375% BDS 22/10/30	8,996.89
			39,804.36

Portfolio Valuation

Account Group Name - The James Crook Memorial Fellowship

Investment	Units / Shares	Book Cost £	Price	Value £	% of Total Portfolio	Gain / (Loss) £	Estimated Income £	Estimated Yield %	Account Code
Government Fixed Income									
Sovereign Debt									
UK GOVT OF 0.125% 30/01/2026 GBP1000 Excludes 154 days accrued interest of £5.11	9,680	8,999	£0.9979	9,659.67	4.5	661	12	0.1	AW/7595.DIM.01
UK GOVT OF 0.25% 31/07/2031 GBP1000 Excludes 153 days accrued interest of £5.24	5,000	3,945	£0.818	4,090.00	1.9	145	12	0.3	AW/7595.DIM.01
UK GOVT OF 0.375% 22/10/2030 GBP1000 Excludes 70 days accrued interest of £7.64	10,617	8,997	£0.8487	9,010.64	4.2	14	40	0.4	AW/7595.DIM.01
UK GOVT OF 3.25% 31/01/2033 GBP1000 Excludes 153 days accrued interest of £128.90	9,462	8,994	£0.9396	8,890.50	4.2	(103)	312	3.5	AW/7595.DIM.01
UK GOVT OF 3.75% 07/03/2027 GBP1000 Excludes 115 days accrued interest of £107.23	9,076	9,044	£1.0006	9,081.00	4.3	37	340	3.8	AW/7595.DIM.01
Investment Grade Corporate Bonds									
Investment Grade Collectives									
ARTEMIS CORPORATE BOND E GBP DIS	7,966,108	7,916	£1.0154	8,088.79	3.8	173	440	5.4	AW/7595.DIM.01
TWENTYFOUR SUSTAINABLE SHORT TERM BOND INCOME AQG GBP	74,779	6,880	£95.47	7,139.15	3.3	259	321	4.5	AW/7595.DIM.01
Equity									
UK Collectives									
ARTEMIS FD MGRS LT ARTEMIS UK SEL FUND G ACC	4,610	6,877	£1.7234	7,944.87	3.7	1,068	173	2.2	AW/7595.DIM.01
IFSL EVENLODE INCOME D INC	4,580,585	11,285	£2.5685	11,765.23	5.5	480	345	2.9	AW/7595.DIM.01
North America Collectives									
BNY MELLON US EQ INC E GBP	5,941,313	9,932	£1.9212	11,414.45	5.4	1,483	192	1.7	AW/7595.DIM.01
DODGE & COX WORLDWIDE US STOCK GBP ACC	135,341	8,067	£63.85	8,641.52	4.1	575	0	0.0	AW/7595.DIM.01
Europe Collectives									
LIONTRUST EUROPEAN DYNAMIC S GBP ACC	2,295,869	3,058	£1.667	3,827.21	1.8	769	63	1.6	AW/7595.DIM.01
Asia Pacific Collectives									
M&G ASIAN STERLING PP GBP DIS	4,532	5,875	£1.4726	6,673.82	3.1	798	193	2.9	AW/7595.DIM.01

Portfolio Valuation

Investment	Units / Shares	Book Cost £	Price	Value £	% of Total Portfolio	Gain / (Loss) £	Estimated Income £	Estimated Yield %	Account Code
Emerging Markets Collectives									
SKYLINE UMBRELLA FUND ICAV ARCA EMERGING MARKET EQUITY A USD	3,808,647	4,064	\$2,634	7,458,08	3.5	3,394	0	0.0	AW/7595.DIM.O1
Global Collectives									
BALLIE GIFFORD RESPONSIBLE GLOBAL EQUITY INCOME W6 INC	9,019,253	13,539	£1,689	15,233,52	7.1	1,694	365	2.4	AW/7595.DIM.O1
FIDELITY GLOBAL DIVIDEND FUND R MDIS (GBP)	9,177,64	9,098	£1,326	12,169,55	5.7	3,072	345	2.8	AW/7595.DIM.O1
GUINNESS GLOBAL EQUITY INCOME Z GBP INC	263,84	8,000	£32,4278	8,555,75	4.0	556	167	2.0	AW/7595.DIM.O1
JPMORGAN GLOBAL GROWTH & INCOME PLC ORD GBPO.05	1,574	7,297	£5.74	9,034,76	4.2	1,738	361	4.0	AW/7595.DIM.O1
MORGAN STANLEY GLOBAL BRANDS PORTFOLIO I GBP ACC HGD	310	6,034	£18,4361	5,715,19	2.7	(319)	0	0.0	AW/7595.DIM.O1
NATIXIS LOOMIS SAYLES GLOBAL GROWTH EQUITY FUND S2A GBP	59,97	10,082	£211.33	12,673,46	5.9	2,592	0	0.0	AW/7595.DIM.O1
Commodity									
Collectives									
X I E PHYSICAL GOLD ETC GBP	301	8,506	£50,135	15,090,64	7.1	6,584	0	0.0	AW/7595.DIM.O1
Absolute Return									
Global Collectives									
TRIUM CLIMATE IMPACT D GBP	34,94	3,662	£103.35	3,611,05	1.7	(51)	0	0.0	AW/7595.DIM.O1
Collectives									
FULCRUM DIVERSIFIED ABSOLUTE RETURN C GBP ACC	46,617	6,468	£172.6	8,046,09	3.8	1,579	65	0.8	AW/7595.DIM.O1
Systematic Trend Other									
AQR MANAGED FUTURES FUND F GBP	55	7,933	£149.76	8,236,80	3.9	304	0	0.0	AW/7595.DIM.O1
Cash									
Cash									
Investment Account GBP	1,008.13	1,008	£1	1,008.13	0.5	0	12	1.2	AW/7595.DIM.O1
Portfolio Totals		185,558		213,032.67	100.0	27,502	3,761	1.8	
Accrued Interest				254.12					
Total (Including Accrued Interest)				213,313.99					